CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
flutamide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00767286
NCT00767286Phase 3Completed
CompareCT.gov

A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE

Radiation Therapy Oncology Group·interventional·Posted Oct 7, 2008·Updated Jan 28, 2014

In Brief

A Phase 3 clinical trial evaluating flutamide, goserelin acetate, and 2 other interventions for Prostate Cancer. Completed.

Detailed Summary

RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
Countries--
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 7, 2008
Study CompletionNov 1, 2003
TodayJul 2, 2026
Posted 17.7 years ago

Interventions

flutamidedrug

goserelin acetatedrug

low-LET cobalt-60 gamma ray therapyradiation

low-LET photon therapyradiation